Vaccinex, Inc.
Vaccinex, Inc., a clinical-stage biotechnology company, discovers and develops bio therapeutics to treat serious diseases and conditions with unmet medical needs. The company offers its products for the treatment of cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is pepinemab that is in clinical development stage for the treatment of non-small cell lung cancer (NSCLC), Huntington's disease, osteosarcoma, melanoma, and Alzheimer's disease. The company is also developing VX5, a human antibody to CXCL13 that is in preclinical development for the treatment of MS and potentially for other autoimmune disorders; and VX25, a bi-specific natural killer T (NKT) cell stimulator, for the therapeutic application of NKT cell stimulation for cancer immunotherapy. It has a clinical trial collaboration and supply agreement with Merck KGaA to test pepinemab in combination with avelumab checkpoint inhibitor in NSCLC patients. Vaccinex, Inc. was founded in 2001 and is headquartered in Rochester, New York. Show More...
-
Website http://www.vaccinex.com
-
Sector Healthcare
-
Industry Biotechnology
-
Last Quote 0.92 USD
-
Last Updated 30-05-2025
-
External Links Yahoo Finance Morningstar Ratios
-
Interest Coverage
The interest coverage ratio is a debt ratio and profitability ratio used to determine how easily a company can pay interest on its outstanding debt.
Reference: Investopedia -
2010-12 2011-12 2012-12 2013-12 2014-12 2015-12 2016-12 2017-12 2018-12 2019-12 TTM Earnings Per Share USD -3.3 -2.69 -5.65 -2.47 -2.13 Dividends USD Payout Ratio % * Shares Mil 8.0 8.0 5.0 13.0 14.0 Book Value Per Share * USD -0.010 -1.35 -1.54 Free Cash Flow Per Share * USD -2.09 -2.71 Return on Assets % -923.05 -323.65 -213.88 -239.28 -329.52 Financial Leverage (Average) Return on Equity % Return on Invested Capital % Interest Coverage -3.66 -12.81 -74.3 Current Ratio 0.48 1.19 3.2 0.58 0.64 Quick Ratio 0.4 1.03 3.05 0.53 0.49 Debt/Equity